The current manuscript is the second update of the original Practical Guide, published in
2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of …

Non–vitamin K oral anticoagulants (NOACs) are now widely used as alternatives to warfarin
for stroke prevention in atrial fibrillation and management of venous thromboembolism. In …

Background: Lifelong oral anticoagulation, either with warfarin or a non–vitamin K
antagonist oral anticoagulant (NOAC), is indicated for stroke prevention in most patients with …

Background Chronic kidney disease (CKD) is an independent risk factor for atrial fibrillation
(AF), which is more prevalent among CKD patients than the general population. AF causes …

Atrial fibrillation (AF) and chronic kidney disease (CKD) are increasingly prevalent in the
general population and share common risk factors such as older age, hypertension and …

Anticoagulant-related nephropathy (ARN) is a newly recognized form of AKI in which
overanticoagulation causes profuse glomerular hemorrhage, which manifests on renal …

Background: Both atrial fibrillation and venous thromboembolism (VTE) are highly prevalent
among patients with chronic kidney disease (CKD). Until recently, warfarin was the most …

Introduction A principal aim of the Global Anticoagulant Registry in the FIELD-Atrial
Fibrillation (GARFIELD-AF) was to document changes in treatment practice for patients with …

Patients with atrial fibrillation (AF) commonly have impaired renal function. The safety and
efficacy of direct oral anticoagulants (DOACs) in patients with chronic kidney disease (CKD) …

Objectives Rivaroxaban (RXB), a novel Xa inhibitor having groundbreaking therapeutic
potential. However, this drug is associated with few limitations, including its …